
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
B-cell Acute Lymphocytic LeukemiaThis study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.

Umbilical Cord Blood Transplantation From Unrelated Donors
Acute LeukemiaImmune Deficiency Disorder8 moreThis study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
GlioblastomaThis is a multi-center, phase II/III, open-label, randomized, parallel and standard chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to receive control treatment or study treatment. The primary objective of this trial is to evaluate the effect of add-on JP001 to standard chemoradiation in increasing overall survival (OS) on newly diagnosed glioblastoma (GBM) patients.

Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
ChordomaComparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
CarcinomaSquamous Cell1 morePatients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity and the level of reactive oxygen species generated by the drug in subjects with squamous cell carcinoma of the head and neck treated on this trial.

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
PlasmacytomaRecurrent Multiple Myeloma1 moreThis phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation
ColoRectal CancerLiver Metastasis Colon Cancer2 moreThe primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive...
Chronic Lymphocytic LeukemiaThis is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.

DAHANCA 37. Re-irradiation With Proton Radiotherapy
Head and Neck NeoplasmsSummary Design Phase II observational Treatment 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively Proton radiotherapy Concomitant cisplatin for eligible patients* Nimorazole recommended for SCC* *The concurrent medical treatment (weekly cisplatin and nimorazole) are prescribed according to the national treatment guidelines, and are not part of the experimental treatment. Endpoints Primary: o Any new late toxicity grade >=3 according to CTC AE 5.0 Secondary Side effects according to DAHANCA scoring system Quality of life and PROM according to EORTC C30 and HN43 Loco-regional control (LRC) Overall survival (OS)

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma...
MeningiomaThis single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk Ga-DOTATATE PET-MRI positive meningioma. Ga-DOTATATE PET-MRI scans will be obtained prior to initiation of Lutathera treatment and 6 months after the initiation of Lutathera treatment. The latter will be performed within the 14 days prior to the last dose of Lutathera treatment.